'Mad Money' host Jim Cramer talks investing in the current market and why it can sometimes feel like a rigged game.
Stock markets are enduring turmoil this August. Since the beginning of the month, the benchmark S&P 500 index has declined 2%.
Jefferies analyst Akash Tewari upgraded shares of Eli Lilly to Buy from Hold.
There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs ha
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the growing interest in new diabetes drugs, with some showing promise for weight loss and heart disease prevention, the promise
Eli Lilly CEO David Ricks joins 'Mad Money' host Jim Cramer to talk the recent stock pop, Eli Lilly weight-loss drug and more.
Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer's drugs. But is LLY stock a buy now?
Dr. Ezekiel Emanuel, fmr. Obama White House health policy advisor, joins 'Last Call' to talk the Eli Lilly's stock reaction to its weight-loss drug, rising obesity rates in the U.S. and more.
The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.
Pharma giant Eli Lilly's (LLY) stock is soaring after reporting a second-quarter earnings beat, boasting revenue of $8.31 billion and earnings of $2.11 per share. Raising its full-year guidance, the p
Mohit Bansal, Wells Fargo equity analyst, joins 'Power Lunch' to discuss Eli Lilly quarterly results as shares soar on Q2 earnings and revenue beats.
The bulk of the Q2 earnings season is in the rearview mirror, with most S&P 500 companies already unveiling their quarterly results. The period has largely been better than feared, helping to inject s
Pharmaceutical giant Eli Lilly (NYSE: LLY ) delighted investors with an impressive earnings performance, sending LLY stock to a new all-time high. In particular, the company's diabetes treatment Mounj
Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE